Rethinking Diabetes: A Weekly Review
Malattie Metaboliche e Diabetologia
GLP-1 Therapies and Beyond: Weight Management to Neuroprotection
This week we explore the expanding applications of GLP-1 therapies - from weight maintenance with orforglipron to neuroprotective potential in Alzheimer's disease. We also cover CGM advancements, renal protection with tirzepatide, and a holistic approach to insulin resistance in aging.
Bibliography
1. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Authors: Aronne LJ, Horn DB, le Roux CW, et al.
Journal: Nature medicine
PMID: 42120723
DOI: 10.1038/s41591-026-04386-7
2. Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design.
Authors: Alva S, Bhargava A, Bode B, et al.
Journal: Journal of diabetes science and technology
PMID: 40183340
DOI: 10.1177/19322968251329364
3. Too much of a good thing.
Authors: Varghese D, Abdelsalam D, Ibrahim S, et al.
Journal: Survey of ophthalmology
PMID: 41520798
DOI: 10.1016/j.survophthal.2026.01.001
4. GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies.
Authors: Wang X, Lin R, Sun Q, et al.
Journal: Pharmacological research
PMID: 42379432
DOI: 10.1016/j.phrs.2026.108331
5. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.
Authors: Zoungas S, D'Alessio D, Pavo I, et al.
Journal: The lancet. Diabetes & endocrinology
PMID: 42114520
DOI: 10.1016/S2213-8587(26)00032-X
6. GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.
Authors: Santiago JA, Gutierrez-Silva JC, Hsu WC, et al.
Journal: Trends in molecular medicine
PMID: 41444101
DOI: 10.1016/j.molmed.2025.12.001
7. Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular-Kidney-Metabolic Syndrome.
Authors: Zeitler E, Klein KR, Lingvay I, et al.
Journal: Diabetes, obesity & metabolism
PMID: 42010373
DOI: 10.1111/dom.70781
8. Rethinking insulin resistance in aging: A reserve-oriented clinical framework.
Authors: Boccardi V, Sinclair AJ
Journal: Ageing research reviews
PMID: 42150705
DOI: 10.1016/j.arr.2026.103180
9. Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.
Authors: Panou T, Gouveri E, Popovic DS, et al.
Journal: Advances in therapy
PMID: 41991874
DOI: 10.1007/s12325-026-03599-z
10. cGAS: bridging immunity and metabolic regulation.
Authors: Wang J, Meng W
Journal: Journal of molecular cell biology
PMID: 40674068
DOI: 10.1093/jmcb/mjaf018
Authors: Aronne LJ, Horn DB, le Roux CW, et al.
Journal: Nature medicine
PMID: 42120723
DOI: 10.1038/s41591-026-04386-7
2. Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design.
Authors: Alva S, Bhargava A, Bode B, et al.
Journal: Journal of diabetes science and technology
PMID: 40183340
DOI: 10.1177/19322968251329364
3. Too much of a good thing.
Authors: Varghese D, Abdelsalam D, Ibrahim S, et al.
Journal: Survey of ophthalmology
PMID: 41520798
DOI: 10.1016/j.survophthal.2026.01.001
4. GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies.
Authors: Wang X, Lin R, Sun Q, et al.
Journal: Pharmacological research
PMID: 42379432
DOI: 10.1016/j.phrs.2026.108331
5. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.
Authors: Zoungas S, D'Alessio D, Pavo I, et al.
Journal: The lancet. Diabetes & endocrinology
PMID: 42114520
DOI: 10.1016/S2213-8587(26)00032-X
6. GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.
Authors: Santiago JA, Gutierrez-Silva JC, Hsu WC, et al.
Journal: Trends in molecular medicine
PMID: 41444101
DOI: 10.1016/j.molmed.2025.12.001
7. Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular-Kidney-Metabolic Syndrome.
Authors: Zeitler E, Klein KR, Lingvay I, et al.
Journal: Diabetes, obesity & metabolism
PMID: 42010373
DOI: 10.1111/dom.70781
8. Rethinking insulin resistance in aging: A reserve-oriented clinical framework.
Authors: Boccardi V, Sinclair AJ
Journal: Ageing research reviews
PMID: 42150705
DOI: 10.1016/j.arr.2026.103180
9. Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.
Authors: Panou T, Gouveri E, Popovic DS, et al.
Journal: Advances in therapy
PMID: 41991874
DOI: 10.1007/s12325-026-03599-z
10. cGAS: bridging immunity and metabolic regulation.
Authors: Wang J, Meng W
Journal: Journal of molecular cell biology
PMID: 40674068
DOI: 10.1093/jmcb/mjaf018
